Comparative Pharmacology
Head-to-head clinical analysis: DETROL LA versus HICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL LA versus HICON.
DETROL LA vs HICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Category C
Category C
Anticholinergic
Anticholinergic